Source: Anti-Cancer Drugs. Unidades: IB, FFCLRP, FMRP
Subjects: OSTEOSSARCOMA (TRATAMENTO), FÁRMACOS, MITOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MORALES, Andressa Gois et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anti-Cancer Drugs, v. 22, n. 10, p. 995-1001, 2011Tradução . . Disponível em: https://doi.org/10.1097/cad.0b013e32834a16d4. Acesso em: 24 jun. 2024.APA
Morales, A. G., Brassesco, M. S., Pezuk, J. A., Oliveira, J. C. de, Montaldi, A. P., Hojo, E. T. S., et al. (2011). BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anti-Cancer Drugs, 22( 10), 995-1001. doi:10.1097/cad.0b013e32834a16d4NLM
Morales AG, Brassesco MS, Pezuk JA, Oliveira JC de, Montaldi AP, Hojo ETS, Scrideli CA, Tone LG. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity [Internet]. Anti-Cancer Drugs. 2011 ; 22( 10): 995-1001.[citado 2024 jun. 24 ] Available from: https://doi.org/10.1097/cad.0b013e32834a16d4Vancouver
Morales AG, Brassesco MS, Pezuk JA, Oliveira JC de, Montaldi AP, Hojo ETS, Scrideli CA, Tone LG. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity [Internet]. Anti-Cancer Drugs. 2011 ; 22( 10): 995-1001.[citado 2024 jun. 24 ] Available from: https://doi.org/10.1097/cad.0b013e32834a16d4